Fabienne Douven, Director Corporate Communications
P.O. Box 7071
6503 GN Nijmegen
T (+31) 24 37 27 700
F (+31) 24 37 27 705
Press release by Leica Biosystems
Best-in-Class potential with improved therapeutic index compared to other armed antibodies.
Synthon today announced that it has entered into a global license agreement with Amgen Inc. (NASDAQ:AMGN) and Watson Pharmaceuticals, Inc. (NYSE:WPI) for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer.
Synthon today announced that it has successfully completed multiple decentralized procedures for two formulations of zoledronic acid. Regulatory approval has been obtained for zoledronic acid concentrate solution for infusion (4 mg / 5 ml) and zoledronic acid solution for infusion (5 mg / 100 ml) in 22 European countries.
Synthon today announced that it has appointed Paul Roos as Chief Financial Officer (CFO). Paul will also serve as a member of Synthon’s executive board.
Synthon extends innovative potential of its biopharmaceutical pipeline and platforms.